Swedish Orphan Biovitrum Appoints Mats-Olof Wallin as Permanent Chief Financial Officer
Published: May 17, 2013
STOCKHOLM, SWEDEN--(Marketwired - May 17, 2013) - Mats-Olof Wallin, who recently took on the role as interim Chief Financial Officer (CFO), has been appointed Senior Vice President and CFO at Swedish Orphan Biovitrum AB (publ.) (Sobi).
After a thorough search process supported by a senior Executive Search firm, Mats-Olof Wallin was selected as the preferred candidate. Wallin brings more than 30 years of experience in the pharmaceutical industry, gained from various executive positions within companies such as Pharmacia, Ortivus and, most recently, Biotage AB (publ.) where he held the role of CFO between 2003 and 2011. Wallin has been working at Sobi for the past several months.
"We are very pleased with the appointment of Mats-Olof as our permanent CFO. We have conducted a thorough search process and Mats-Olof has emerged as the most suitable candidate for the job. He brings significant experience to the role and has already proven to be a great addition to our senior team", said CEO Geoffrey McDonough.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (EUR 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com
Sobi appoints permanent CFO: http://hugin.info/134557/R/1702768/562704.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
For more information - not for publication
Head of Communications
T: +46 70 410 71 80
Vice President, Head of Investor Relations
T: +46 8 697 20 00
Help employers find you! Check out all the jobs and post your resume.